BNP Paribas Asset Management
MRNA icon

BNP Paribas Asset Management’s Moderna MRNA Stock Holding History

BNP Paribas Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Buy
44,352
+11,254
+34% +$582K ﹤0.01% 1017
2026
Q1 		$1.68M Buy
33,098
+2,008
+6% +$93.7K ﹤0.01% 1102
2025
Q4 		$921K Buy
31,090
+3,387
+12% +$92K ﹤0.01% 1181
2025
Q3 		$712K Sell
27,703
-66,213
-71% -$1.85M ﹤0.01% 708
2025
Q2 		$2.59M Sell
93,916
-27,811
-23% -$732K 0.01% 676
2025
Q1 		$3.46M Buy
121,727
+48,529
+66% +$1.72M 0.01% 609
2024
Q4 		$3.04M Sell
73,198
-12,275
-14% -$587K 0.01% 645
2024
Q3 		$5.71M Buy
85,473
+29,177
+52% +$2.68M 0.01% 519
2024
Q2 		$6.68M Sell
56,296
-37,172
-40% -$4.7M 0.02% 484
2024
Q1 		$9.96M Sell
93,468
-205,609
-69% -$20.7M 0.03% 430
2023
Q4 		$29.7M Buy
299,077
+242,781
+431% +$20.4M 0.08% 248
2023
Q3 		$5.82M Buy
56,296
+12,131
+27% +$1.35M 0.02% 490
2023
Q2 		$5.37M Buy
44,165
+1,100
+3% +$147K 0.02% 505
2023
Q1 		$6.61M Sell
43,065
-35,971
-46% -$5.93M 0.02% 483
2022
Q4 		$14.2M Sell
79,036
-16,009
-17% -$2.62M 0.05% 370
2022
Q3 		$11.2M Sell
95,045
-34,234
-26% -$5.19M 0.04% 392
2022
Q2 		$18.5M Sell
129,279
-84,138
-39% -$12M 0.07% 295
2022
Q1 		$36.8M Buy
213,417
+87,758
+70% +$14.8M 0.13% 196
2021
Q4 		$31.9M Buy
125,659
+51,353
+69% +$15M 0.11% 234
2021
Q3 		$28.6M Buy
74,306
+51,308
+223% +$18.9M 0.11% 228
2021
Q2 		$5.41M Buy
22,998
+16,668
+263% +$2.98M 0.02% 534
2021
Q1 		$829K Buy
6,330
+170
+3% +$24.6K ﹤0.01% 739
2020
Q4 		$644K Sell
6,160
-634
-9% -$64.1K ﹤0.01% 742
2020
Q3 		$481K Sell
6,794
-40
-0.6% -$2.79K ﹤0.01% 745
2020
Q2 		$439K Buy
+6,834
New +$374K ﹤0.01% 708

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

BNP Paribas Asset Management's MRNA Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Moderna (MRNA) stake by 34% in Q2 2026, buying an estimated $582K and bringing the position to 44,352 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1017.

BNP Paribas Asset Management first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $36.8M in Q1 2022. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • BNP Paribas Asset Management held 44,352 shares of Moderna worth $3.11M as of Q2 2026.
  • BNP Paribas Asset Management bought 11,254 Moderna shares in Q2 2026, an estimated $582K.
  • Moderna made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1017 holding.
  • BNP Paribas Asset Management first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • BNP Paribas Asset Management's Moderna position peaked at $36.8M in Q1 2022.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.